AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30141338 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally and linguistically appropriate communication strategies (storytelling or visual presentation)
Number of subjects: 19
Study 30141338 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of mothers' intention on HPV vaccination
Number of subjects: 19
Study 30141338 — intervention group
Group type: COMPARATOR
Intervention: Current practice of using information-based written materials
Number of subjects: 19
Study 31724343 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation AH
Number of subjects: 0
Study 31724343 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation AK
Number of subjects: 0
Study 31724343 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal effect
Number of subjects: 0
Study 31724343 — intervention group
Group type: COMPARATOR
Intervention: Reference (single-entity tablets)
Number of subjects: 0
Study 29891263 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation with hippocampus avoidance (PCI-HA)
Number of subjects: 150
Study 29891263 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylactic cranial irradiation (PCI)
Number of subjects: 150
Study 28776077 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel formulation of abiraterone acetate (100 mg in fasted state)
Number of subjects: 11
Study 28776077 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel formulation of abiraterone acetate (200 mg in fasted state)
Number of subjects: 11
Study 28776077 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel formulation of abiraterone acetate (200 mg in fed state)
Number of subjects: 11
Study 28776077 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel formulation of abiraterone acetate
Number of subjects: 11
Study 28776077 — intervention group
Group type: COMPARATOR
Intervention: Zytiga (1000 mg)
Number of subjects: 11
Study 26140829 — intervention group
Group type: EXPERIMENTAL
Intervention: White light imaging followed by narrow band imaging (WL/NBI)
Number of subjects: 148
Study 26140829 — intervention group
Group type: COMPARATOR
Intervention: White light imaging only (WL/WL)
Number of subjects: 148
Study 23640558 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (individually tailored, supervised, for six weeks)
Number of subjects: 48
Study 23640558 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 48
Study 23640558 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups after six weeks
Number of subjects: 48
Study 21703101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal carbon dioxide (CO(2))
Number of subjects: 12
Study 21703101 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (no CO(2))
Number of subjects: 12
Study 18489933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 150
Study 18489933 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 150
Study 17178269 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban
Number of subjects: 119
Study 17178269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 14652643 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Certoparin application
Number of subjects: 360
Study 14652643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 11064980 — intervention group
Group type: EXPERIMENTAL
Intervention: All-polyethylene tibial component
Number of subjects: 296
Study 11064980 — intervention group
Group type: COMPARATOR
Intervention: Metal-backed tibial component
Number of subjects: 296
Study 8976308 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine acupuncture
Number of subjects: 10
Study 8976308 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 10
Study 8976308 — intervention group
Group type: COMPARATOR
Intervention: Rest without needles being inserted
Number of subjects: 10
Study 1291203 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed with supplementary zinc 1.14-2.28 mg/kg/d
Number of subjects: 102
Study 1291203 — intervention group
Group type: COMPARATOR
Intervention: Formula-fed and supplemented with Vitamin B complex as placebo
Number of subjects: 102
Study 6439639 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperosmolar basic nutrition solution (3% amino acids, carbohydrates and electrolytes, 806 mosm/l)
Number of subjects: 24
Study 6439639 — intervention group
Group type: COMPARATOR
Intervention: Isoosmolar electrolyte solution (299 mosm/l)
Number of subjects: 24
Study 29528793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib (5 mg once daily in 4-week cycles of 3 weeks on, 1 week off)
Number of subjects: 91
Study 29528793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Number of subjects: 91
Study 29528793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 25341680 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized education programme in addition to standard care
Number of subjects: 40
Study 25341680 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 25312546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving feedback regarding assessment results and recommendations for subsequent treatment.
Number of subjects: 286
Study 25312546 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving treatment as usual and global feedback regarding assessment results without recommendations.
Number of subjects: 286
Study 24144944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate (NaPBA) and glycerol phenylbutyrate (GPB, HPN‐100)
Number of subjects: 4683
Study 24144944 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PAA:PAGN ratio
Number of subjects: 4683
Study 21243280 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 40
Study 21243280 — intervention group
Group type: COMPARATOR
Intervention: Control (no massage therapy)
Number of subjects: 40
Study 18456137 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded OMIs (up to 250 g of direct force applied immediately)
Number of subjects: 13
Study 18456137 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed loaded OMIs (loaded 3 to 5 weeks later)
Number of subjects: 13
Study 18456137 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded OMIs (combined)
Number of subjects: 13
Study 18456137 — intervention group
Group type: COMPARATOR
Intervention: Unloaded OMIs
Number of subjects: 13
Study 18456137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain during OMI placement
Number of subjects: 13
Study 18456137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain during OMI removal
Number of subjects: 13
Study 17080220 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment for glycaemic control
Number of subjects: 20
Study 17080220 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic subjects (reference group)
Number of subjects: 20
Study 17080220 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects
Number of subjects: 20
Study 11802928 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire with intimate questions; Sample mailed to laboratory
Number of subjects: 750
Study 11802928 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire without intimate questions; Sample mailed to laboratory
Number of subjects: 750
Study 11802928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample delivered to physician's office (men)
Number of subjects: 750
Study 11802928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample mailed to laboratory (women)
Number of subjects: 750
Study 10030506 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic treatment suggestions for heart failure, ischemic heart disease, reactive airways disease, and uncomplicated hypertension.
Number of subjects: 28
Study 10030506 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to electronic treatment suggestions).
Number of subjects: 28
Study 7554309 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter)
Number of subjects: 63
Study 2256971 — intervention group
Group type: EXPERIMENTAL
Intervention: One-injection-site peribulbar anesthesia
Number of subjects: 100
Study 2256971 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 100
Study 6445180 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 165
Study 6445180 — intervention group
Group type: COMPARATOR
Intervention: Delayed cholecystectomy
Number of subjects: 165
Study 29945252 — intervention group
Group type: EXPERIMENTAL
Intervention: L-AmB 10 mg/kg on day 1 (single dose)
Number of subjects: 80
Study 29945252 — intervention group
Group type: EXPERIMENTAL
Intervention: L-AmB 10 mg/kg on day 1 and 5 mg/kg on day 3 (2 doses)
Number of subjects: 80
Study 29945252 — intervention group
Group type: EXPERIMENTAL
Intervention: L-AmB 10 mg/kg on day 1 and 5 mg/kg on days 3 and 7 (3 doses)
Number of subjects: 80
Study 29945252 — intervention group
Group type: COMPARATOR
Intervention: L-AmB 3 mg/kg/day for 14 days (control)
Number of subjects: 80
Study 27465063 — intervention group
Group type: EXPERIMENTAL
Intervention: End-task feedback (ET)
Number of subjects: 65
Study 27465063 — intervention group
Group type: COMPARATOR
Intervention: In-task feedback (IT)
Number of subjects: 65
Study 26360284 — intervention group
Group type: EXPERIMENTAL
Intervention: D-serine (60 mg/kg) given orally in divided daily doses for 16 weeks
Number of subjects: 44
Study 26360284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 24335106 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 846
Study 24335106 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 846
Study 24335106 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 846
Study 22531678 — intervention group
Group type: EXPERIMENTAL
Intervention: pH1N1/09 case definition for influenza exposure
Number of subjects: 19
Study 22531678 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza exposure
Number of subjects: 19
Study 19400023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and dorsiflexion range of motion
Number of subjects: 150
Study 19400023 — intervention group
Group type: COMPARATOR
Intervention: Fracture management, fracture severity, baseline activity limitation, pain, mobility and dorsiflexion range of motion
Number of subjects: 150
Study 17304425 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg/d enteral iron polymaltose complex (IPC) at 2 weeks of age
Number of subjects: 68
Study 17304425 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg/d enteral iron polymaltose complex (IPC) at 4 weeks of age
Number of subjects: 68
Study 15216537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional photothermolysis (FP) with micro‐exposures of variable MTZ density on forearms
Number of subjects: 45
Study 15216537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional photothermolysis (FP) on periorbital area
Number of subjects: 45
Study 11114277 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strength training (FM(T))
Number of subjects: 21
Study 11114277 — intervention group
Group type: COMPARATOR
Intervention: Control group (FM(C))
Number of subjects: 21
Study 11114277 — intervention group
Group type: COMPARATOR
Intervention: Healthy training group (H(T))
Number of subjects: 21
Study 10206032 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of 1% hyperbaric bupivacaine injected over 40 sec (Group SLOW)
Number of subjects: 30
Study 10206032 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of 1% hyperbaric bupivacaine injected over 3 sec (Group FAST)
Number of subjects: 30
Study 7798076 — intervention group
Group type: EXPERIMENTAL
Intervention: Pull-out program for gifted students
Number of subjects: 60
Study 2129376 — intervention group
Group type: EXPERIMENTAL
Intervention: 750,000 and 1.5 mio U streptokinase (SK)
Number of subjects: 40
Study 2129376 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg anisoylated plasminogen streptokinase activator complex (BRL 26921)
Number of subjects: 40
Study 2129376 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 U urokinase (UK) and 4.5 mio U pro‐urokinase (PUK)
Number of subjects: 40
Study 2129376 — intervention group
Group type: EXPERIMENTAL
Intervention: SK groups (750,000 and 1.5 mio U)
Number of subjects: 40
Study 2129376 — intervention group
Group type: EXPERIMENTAL
Intervention: BRL 26921
Number of subjects: 40
Study 2129376 — intervention group
Group type: EXPERIMENTAL
Intervention: SK
Number of subjects: 40
Study 520990 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg daily etiroxate hydrochloride
Number of subjects: 0
Study 520990 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg daily etiroxate hydrochloride
Number of subjects: 0
Study 520990 — intervention group
Group type: EXPERIMENTAL
Intervention: etiroxate hydrochloride
Number of subjects: 0
Study 31826936 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-detection time (NID 30/40)
Number of subjects: 1902
Study 31826936 — intervention group
Group type: COMPARATOR
Intervention: Nominal detection time (NID 18/24)
Number of subjects: 1902
Study 31755625 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment - on target (below 130 mm Hg)
Number of subjects: 0
Study 31755625 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment - on target (below 140 mm Hg)
Number of subjects: 0
Study 31755625 — intervention group
Group type: COMPARATOR
Intervention: Intensive treatment - on target
Number of subjects: 0
Study 28485075 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 20
Study 28485075 — intervention group
Group type: COMPARATOR
Intervention: Plasma Exchange (PE)
Number of subjects: 20
Study 26509147 — intervention group
Group type: EXPERIMENTAL
Intervention: CE model with treatment effect
Number of subjects: 3
Study 26509147 — intervention group
Group type: COMPARATOR
Intervention: Placebo subjects
Number of subjects: 3
Study 26509147 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparse sampling
Number of subjects: 3
Study 24624861 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Voluven (HES 130/0.4)
Number of subjects: 0
Study 24624861 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (normal saline solution)
Number of subjects: 0
Study 20921019 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 1069
Study 20921019 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Invasive Positive Pressure Ventilation (NIPPV)
Number of subjects: 1069
Study 20921019 — intervention group
Group type: COMPARATOR
Intervention: Standard Oxygen Therapy
Number of subjects: 1069
Study 19819210 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine
Number of subjects: 137
Study 18024876 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cisplatin chemotherapy (NACT) before radiotherapy (RT) or chemoradiotherapy (CRT)
Number of subjects: 0
Study 18024876 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 0
Study 18024876 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-containing regimens
Number of subjects: 0
Study 18024876 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy followed by RT or CRT
Number of subjects: 0
Study 12925047 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetic pregnancies
Number of subjects: 913
Study 12925047 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-diabetic pregnancies
Number of subjects: 913
Study 12925047 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic pregnancies (control)
Number of subjects: 913
Study 10499382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosedation (hypnosis in combination with conscious IV sedation and local anaesthesia)
Number of subjects: 0
Study 10499382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0
Study 10499382 — intervention group
Group type: COMPARATOR
Intervention: Normal alertness
Number of subjects: 0
Study 8877349 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (2 mg/kg/day)
Number of subjects: 36
Study 8877349 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (1 mg/kg/day)
Number of subjects: 36
Study 1496699 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine base 25 mg/kg
Number of subjects: 98
Study 1496699 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine base 25 mg/kg
Number of subjects: 98
Study 1496699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulfadoxine plus 3 days of quinine
Number of subjects: 98
Study 6357536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (n = 8)
Number of subjects: 15
Study 6357536 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose in water (n = 7)
Number of subjects: 15
Study 2948270 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (75 mg)
Number of subjects: 10
Study 2948270 — intervention group
Group type: COMPARATOR
Intervention: Zimelidine (100 mg)
Number of subjects: 10
Study 29520872 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a 180 μg/wk × 48 weeks (group 4)
Number of subjects: 383
Study 29520872 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa‐2a 90 μg/wk × 24 weeks (group 1)
Number of subjects: 383
Study 29520872 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa‐2a 90 μg/wk × 48 weeks (group 3)
Number of subjects: 383
Study 29520872 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa‐2a 180 μg/wk × 24 weeks (group 2)
Number of subjects: 383
Study 27549751 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-supported care
Number of subjects: 26
Study 27549751 — intervention group
Group type: COMPARATOR
Intervention: Specialist nursing intervention
Number of subjects: 26
Study 24738461 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg tamsulosin + 5 mg solifenacin (mild obstruction symptom group)
Number of subjects: 166
Study 24738461 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg tamsulosin (mild obstruction symptom group)
Number of subjects: 166
Study 24738461 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg tamsulosin + 5 mg solifenacin (moderate obstruction symptom group)
Number of subjects: 166
Study 24738461 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg tamsulosin (moderate obstruction symptom group)
Number of subjects: 166
Study 22939276 — intervention group
Group type: EXPERIMENTAL
Intervention: ArterX Vascular Sealant (AVS)
Number of subjects: 217
Study 22939276 — intervention group
Group type: COMPARATOR
Intervention: Gelfoam Plus (Control)
Number of subjects: 217
Study 20732607 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compression-only CPR
Number of subjects: 213
Study 20732607 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPR
Number of subjects: 213
Study 19034105 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (25, 50, 100, or 200 microg x kg x min)
Number of subjects: 166
Study 19034105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 16157899 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-3 (150 microg/kg, subcutaneously, three times a week for 6 months)
Number of subjects: 8
Study 16157899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12960539 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (n = 35)
Number of subjects: 70
Study 12960539 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (n = 35)
Number of subjects: 70
Study 10469854 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/d) treated hemodialysis patients (+ACEi)
Number of subjects: 33
Study 10469854 — intervention group
Group type: COMPARATOR
Intervention: Untreated hemodialysis patients (-ACEi)
Number of subjects: 33
Study 10469854 — intervention group
Group type: COMPARATOR
Intervention: Pre-HD hemodialysis patients
Number of subjects: 33
Study 10469854 — intervention group
Group type: COMPARATOR
Intervention: Post-HD hemodialysis patients
Number of subjects: 33
Study 8896312 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril
Number of subjects: 22
Study 8896312 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 1985031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pernicious anemia patients
Number of subjects: 28
Study 1985031 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic control subjects
Number of subjects: 28
Study 6846276 — intervention group
Group type: EXPERIMENTAL
Intervention: Quibron‐T/SR
Number of subjects: 13
Study 6846276 — intervention group
Group type: COMPARATOR
Intervention: Theo‐Dur
Number of subjects: 13
Study 31646953 — intervention group
Group type: EXPERIMENTAL
Intervention: High threat condition
Number of subjects: 0
Study 31646953 — intervention group
Group type: EXPERIMENTAL
Intervention: High efficacy condition
Number of subjects: 0
Study 31646953 — intervention group
Group type: COMPARATOR
Intervention: Low threat condition
Number of subjects: 0
Study 31646953 — intervention group
Group type: COMPARATOR
Intervention: Low efficacy condition
Number of subjects: 0
Study 31646953 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy (high vs low)
Number of subjects: 0
Study 31646953 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat (high vs low)
Number of subjects: 0
Study 30766550 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercises in addition to diet regimen
Number of subjects: 80
Study 30766550 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 80
Study 27558249 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic tennis elbow release (ECRB release)
Number of subjects: 0
Study 27558249 — intervention group
Group type: COMPARATOR
Intervention: Sham lateral portal (no ECRB release)
Number of subjects: 0
Study 24614337 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet plus exercise (LoGIX)
Number of subjects: 27
Study 24614337 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic index diet plus exercise (HiGIX)
Number of subjects: 27
Study 22452841 — intervention group
Group type: EXPERIMENTAL
Intervention: Topicaine (4% lidocaine)
Number of subjects: 25